U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07113691) titled 'Iadademstat + SBRT With Atezo in ES-SCLC' on July 28.
Brief Summary: This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy; participants who have achieved only stable disease at the completion of initial platinum-based treatment are eligible for enrollment.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Intervention:
DRUG: Iadademstat
Iadademstat is administered orally (PO) on ...